Next generation inhibitors help overcome problems of resistance in ALK positive lung cancer

Bookmark and Share
Published: 31 May 2015
Views: 3115
Dr Ross Camidge - University of Colorado, Denver, USA

Dr Camidge talks to ecancertv at ASCO 2015 about new treatments for anaplastic lymphoma kinase (ALK) positive lung cancer, including alectinib and brigatinib.